Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk

Journal of the National Cancer Institute

Volumn 106, Issue 2, 2014, Pages

  Makar, George A ^a   Holmes, John H ^a   Yang, Yu Xiao ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROTECTIVE AGENT;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COLORECTAL TUMOR; DRUG ADMINISTRATION; FACTUAL DATABASE; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; MALE; MEDICAL RECORD; MIDDLE AGED; RISK; STATISTICAL MODEL; UNITED KINGDOM;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICARCINOGENIC AGENTS; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREAT BRITAIN; HUMANS; HYPERTENSION; INCIDENCE; LOGISTIC MODELS; MALE; MEDICAL RECORDS; MIDDLE AGED; ODDS RATIO; PROTECTIVE AGENTS; RISK;

EID: 84893850221     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt374     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med. 1985;105(2):141-145.
3. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339(6219):58-61.
4. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68(2):450-456.
5. Taylor GM, Cook HT, Sheffield EA, Hanson C, Peart WS. Renin in blood vessels in human pulmonary tumors. An immunohistochemical and biochemical study. Am J Pathol. 1988;130(3):543-551.
6. Chiu T, Santiskulvong C, Rozengurt E. ANG II stimulates PKC-dependent ERK activation, DNA synthesis, and cell division in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2003;285(1):G1-11.
7. Yasumaru M, Tsuji S, Tsujii M, et al. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulinlike growth factor I receptor pathway. Cancer Res. 2003;63(20):6726-6734.
8. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352(9123):179-184.
9. Friis S, Sorensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer. 2001;92(9):2462-2470.
10. McMenamin UC, Murray LJ, Cantwell MM, Hughes CM. Angiotensinconverting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control. 2012;23(2):221-230.
11. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324, 168 participants from randomised trials. Lancet Oncol. 2011;12(1):65-82.
12. Kedika R, Patel M, Pena Sahdala HN, Mahgoub A, Cipher D, Siddiqui AA. Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps. J Clin Gastroenterol. 2011;45(2):e12-e16.
13. Boudreau DM, Koehler E, Rulyak SJ, Haneuse S, Harrison R, Mandelson MT. Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3076-3080.
14. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology. 2001;12(1):88-93.
15. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics. Mar. 1984;40(1):63-75.
16. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2013. http://www.whocc.no/atcddd/. Accessed December 10, 2013.
17. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129(1):125-137.
18. Assimes TL, Elstein E, Langleben A, Suissa S. Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf. 2008;17(11):1039-1049.
19. Sorensen HT, Olsen JH, Mellemkjaer L, et al. Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer. 2000;89(1):165-170.
20. Olsen JH, Sorensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension. 1997;29(5):1091-1094.
21. Zacharski LR, Moritz TE, Haakenson CM, et al. Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study. Cancer Invest. 1990;8(5):451-458.
22. Scholze J, Grimm E, Herrmann D, Unger T, Kintscher U. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation. 2007;115(15):1991-1998.
23. Galletti F, Strazzullo P, Capaldo B, et al. Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). J Hypertens. 1999;17(3):439-445.
24. Masuo K, Mikami H, Ogihara T, Tuck ML. Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens. 2001;14(6 Pt 1):530-538.
25. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. 2007;133(3):748-754.